Clinical Trials

List clinical trials by disease

Search Clinical Trials

The results of your search are listed below. To view the details of a trial or study, click on the "see details >>" link. Or start a new search.

Searched for: Non-Hodgkin's Lymphoma (NHL). 30 results shown below.

Autologous Stem Cell Transplant Followed By Donor Stem Cell Transplant In Treating Patients With Relapsed or Refractory Lymphoma

[Complete title: A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Non-Myeloablative Allogeneic Stem Cell Transplantation for Patients with Relapsed or Refractory Lymphoma - A Multi-Center Trial]
Principal Investigator: David Maloney, MD, PhD
Study Number: 1409.00
Phase: I/II

Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-Cell Lymphoma

[Complete title: Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Relapsed or Refractory CD20+ B-Cell Malignancies]
Principal Investigator: Andrew Rezvani, MD
Study Number: 2226.00
Phase: II

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Non-Hodgkin Lymphoma

[Complete title: Bortezomib and Vorinostat as Maintenance Therapy after Autologous Transplant for Non-Hodgkin’s Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: 2292.00
Phase: II

Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

[Complete title: Mobilization of Autologous Peripheral Blood Stem Cells (PBSC) in CD20+ Lymphoma Patients Using RICE, G-CSF (Granulocyte-Colony Stimulating Factor), and Plerixafor]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: 2310.00
Phase: II

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

[Complete title: A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (anti-CD45) Antibody followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies]
Principal Investigator: Ajay Gopal, MD
Study Number: 2361.00
Phase: I

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

[Complete title: A phase II trial of high-dose 90Y-Ibritumomab tiuxetan (anti-CD20) followed by fludarabine and low-dose total body irradiation and HLA-matched allogeneic hematopoietic transplantation for patients with relapsed or refractory aggressive B-cell lymphoma]
Principal Investigator: Ajay Gopal, MD
Study Number: 2398.00
Phase: II

Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

[Complete title: A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL/SLL/PLL or NHL with Lenalidomide alone or with Rituximab]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 2467.00
Phase: II

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With Previously Untreated HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma

[Complete title: AMC PROTOCOL #075: A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin’s Lymphoma. A Trial of the AIDS Malignancy Consortium (AMC)]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2483.00
Phase: I/II

Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents
Principal Investigator: Oliver Press, MD, PhD
Study Number: 2609.00
Phase: NA

Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

[Complete title: Idarubicin, Cytarabine and Pravastatin (IAP) for Induction of Newly Diagnosed Acute Myeloid Leukemia (AML)]
Principal Investigator: Raya Mawad
Study Number: 2674.00
Phase: II

Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma

[Complete title: A Phase II Prospective Non-Randomized Two-Arm Clinical Trial of Dose-Adjusted Schedule of Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma (CTCL) Who Did Not Receive Prior Systemic Therapy or Have Been Treated with Single Agent Targretin]
Principal Investigator: Andrei Shustov, MD
Study Number: 6914
Phase: II

Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant

[Complete title: Pentostatin and Donor Lymphocyte Infusion for Low Donor T-Cell Chimerism After Hematopoietic Cell Transplantation - A Multicenter Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 1825.00
Phase: I/II

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant For Hematologic Cancer

[Complete title: A Multi-Center Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil]
Principal Investigator: David Maloney, MD, PhD
Study Number: 1898.00
Phase: II

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease

[Complete title: Transplantation of Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2010.00
Phase: II

A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies

[Complete title: A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Umbilical Cord Blood Progenitors With an Unmanipulated Cord Blood Graft in Patients Undergoing Umbilical Cord Blood Transplantation for Hematologic Malignancies: A Multi-Center Trial Coordinated by the FHCRC]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2044.00
Phase: I

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

[Complete title: A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2230.00
Phase: II

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

[Complete title: Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT using Related, HLA-Haploidentical Donors for Patients with High-Risk lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 2241.00
Phase: II

CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant

[Complete title: A Phase I/II Study of Cellular Immunotherapy with Donor Central Memory-Derived Virus-Specific CD8+ T-Cells Engineered to Target CD19 for CD19+ Malignancies after Allogeneic Hematopoietic Stem Cell Transplant]
Principal Investigator: Cameron Turtle, PhD, MBBS
Study Number: 2494.00
Phase: I/II

Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

[Complete title: Donor Statin Treatment for Prevention of Severe Acute GVHD after Myeloablative Hematopoietic Cell Transplantation]
Principal Investigator: Marco Mielcarek, MD
Study Number: 2545.00
Phase: II

Donor Atorvastatin -Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplantation

[Complete title: Donor Statin Treatment for Prevention of Severe Acute GVHD after Nonmyeloablative Hematopoietic Cell Transplantation]
Principal Investigator: Marco Mielcarek, MD
Study Number: 2546.00
Phase: II

Double Cord vs. Haploidentical (BMT CTN #1101)

[Complete title: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies]
Principal Investigator: Paul O'Donnell, MD, PhD
Study Number: 2580.00
Phase: III

A Phase I study of the Raf kinase and receptor tyrosine kinase inhibitor Sorafenib (BAY 43-9006, NSC# 724772 IND# 69896) in children with refractory solid tumors or refractory leukemias
Principal Investigator: Julie Park, MD
Study Number: COG ADVL0413
Phase: I

A Phase I Study of Temozolomide, oral Irinotecan and Vincristine for Children with Refractory Solid Tumors
Principal Investigator: Julie Park, MD
Study Number: COG ADVL0414
Phase: I

A Phase 1 Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

[Complete title: A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin’s Lymphoma (NHL)]
Principal Investigator: Ajay Gopal, MD
Study Number: 20110654
Phase: I

A Study of Brentuximab Vedotin in Patients With CD30-positive Non-Hodgkin Lymphoma

[Complete title: A phase 2 study of brentuximab vedotin in relapsed or refractory CD30-positive non-Hodgkin lymphoma (NHL)]
Principal Investigator: Andrei Shustov, MD
Study Number: 20110853
Phase: II

Study to Learn if Two Doses of a Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer

[Complete title: A Phase II Trial to Evaluate the Efficacy of Fostamatinib inPatients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)]
Principal Investigator: Andrei Shustov, MD
Study Number: 20111975
Phase: II

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

[Complete title: A Phase 3 Randomized, Two-Arm, Open Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator’s Choice (Selected Single Agent) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma]
Principal Investigator: Andrei Shustov, MD
Study Number: 20120291
Phase: III

A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)

[Complete title: An open-label, multicenter, randomized, Phase III study to investigate the efficacy and safety of bendamustine compared with bendamustine + RO5072759 (GA101) in patients with rituximab-refractory, indolent non-Hodgkin’s lymphoma]
Principal Investigator: Oliver Press, MD, PhD
Study Number: 2388.00
Phase: III

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

[Complete title: A Phase 1/2a, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous Administration of RGI-2001 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)]
Principal Investigator: Paul Martin, MD
Study Number: 2538.00
Phase: I/II

A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma

[Complete title: A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DCDT2980S in Combination with Rituximab or DCDS4501A in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma]
Principal Investigator: Oliver Press, MD, PhD
Study Number: 2649.00
Phase: II

Search Options

Select a disease from the list below:
Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:
Limit results to studies enrolling:

OR

View all studies
Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.